Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FB-1603
- Development stage
- Phase 2
- Lead developer
- Far East Bio-Tec
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
FB-1603 is an orally administered small molecule drug developed by Far East Bio-Tec for the treatment of liver cancer, specifically hepatocellular carcinoma. It is currently being evaluated in Phase 1/2 clinical trials to assess its safety and efficacy in improving liver function impairment in patients with hepatocellular carcinoma, including those receiving transarterial chemoembolization. The drug aims to improve liver function parameters such as AST, ALT, and total bilirubin over a 10-week treatment period[2][3][4][5]. While the precise mechanism of action has not been disclosed publicly as of April 2025, it is positioned as a novel therapeutic candidate for neoplasms affecting the digestive system.
Beyond the preview
Go deeper on FB-1603.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FB-1603.